HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Phase 3 SUNMO Data Show Mosun-Pola Cuts Progression Risk Over R-GemOx in Large B-Cell Lymphoma: Elizabeth Budde, MD, PhD

Phase 3 SUNMO Data Show Mosun-Pola Cuts Progression Risk Over R-GemOx in Large B-Cell Lymphoma: Elizabeth Budde, MD, PhD

By AJMC · May 31, 2026 · via AJMC

This is an aggregated industry headline. Read the full story at AJMC →

Tags
theweekformat:headlineheadlineAJMC
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
ASCO: Sac-TMT's massive phase 3 program has a jarring gap. Does Merck plan to close it?
The WeekFiercePharma ↗
ASCO: Sac-TMT's massive phase 3 program has a jarring gap. Does Merck plan to close it?
Merck & Co.'s extensive clinical development scheme for its TROP2 antibody-drug conjugate sac-TMT already …
Jun 1, 2026
Lilly pens $1.2B deal for Hanmi's GLP-2 drug being aimed at short bowel syndrome
The WeekFierceBiotech ↗
Lilly pens $1.2B deal for Hanmi's GLP-2 drug being aimed at short bowel syndrome
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-s…
Jun 1, 2026
Revolution Medicines Preps Daraxonrasib FDA Filing, Starts Early Shipments
The WeekBriefing
Revolution Medicines Preps Daraxonrasib FDA Filing, Starts Early Shipments
CEO Mark Goldsmith says the company will soon seek approval for its pancreatic cancer drug daraxonrasib and ha…
Jun 1, 2026